PMID- 19802651
OWN - NLM
STAT- MEDLINE
DCOM- 20100506
LR  - 20161125
IS  - 1439-7609 (Electronic)
IS  - 1439-7595 (Linking)
VI  - 20
IP  - 1
DP  - 2010 Feb
TI  - Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid 
      arthritis patients refractory to antitumor necrosis factor biologics.
PG  - 40-5
LID - 10.1007/s10165-009-0235-4 [doi]
AB  - We evaluated the short-term effects of the anti-interleukin-6 (IL-6) receptor 
      antibody tocilizumab (TCZ) in six patients with rheumatoid arthritis (RA) who had 
      been refractory to tumor necrosis factor (TNF) antagonist therapy. All subjects 
      were considered to be secondary nonresponders to TNF antagonists as decided by 
      each physician. The Disease Activity Score of 28 Joints (DAS28) appeared to 
      improve slowly by TCZ compared with TNF antagonist therapy, but significantly 
      decreased at 24 weeks. One patient achieved DAS28 remission [DAS28-erythrocyte 
      sedimentation rate (ESR) <2.60, and 5 of 6 patients showed good or moderate 
      clinical response. The change in the clinical Disease Activity Index was similar 
      to that of the DAS28-ESR. The serum level of matrix metalloproteinase-3 (MMP-3), 
      a marker for synovial overgrowth, also significantly decreased after the 
      treatment (518 +/- 567 at baseline, 141 +/- 90 ng/ml at 24 weeks, p < 0.05). One 
      patient discontinued TCZ because of tuberculous peritonitis. Although physicians 
      need to watch for infectious adverse events, these data indicate that TCZ is 
      effective for treating RA patients refractory to TNF antagonists.
FAU - Kawashiri, Shin-ya
AU  - Kawashiri SY
AD  - Unit of Translational Medicine, Department of Immunology and Rheumatology, 
      Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, 
      Nagasaki, 852-8501, Japan.
FAU - Kawakami, Atsushi
AU  - Kawakami A
FAU - Iwamoto, Naoki
AU  - Iwamoto N
FAU - Fujikawa, Keita
AU  - Fujikawa K
FAU - Aramaki, Toshiyuki
AU  - Aramaki T
FAU - Tamai, Mami
AU  - Tamai M
FAU - Arima, Kazuhiko
AU  - Arima K
FAU - Ichinose, Kunihiro
AU  - Ichinose K
FAU - Kamachi, Makoto
AU  - Kamachi M
FAU - Yamasaki, Satoshi
AU  - Yamasaki S
FAU - Nakamura, Hideki
AU  - Nakamura H
FAU - Origuchi, Tomoki
AU  - Origuchi T
FAU - Ida, Hiroaki
AU  - Ida H
FAU - Eguchi, Katsumi
AU  - Eguchi K
LA  - eng
PT  - Journal Article
DEP - 20091003
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - FYS6T7F842 (Adalimumab)
RN  - I031V2H011 (tocilizumab)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adalimumab
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/blood/*drug therapy/physiopathology
MH  - Biomarkers/blood
MH  - Drug Resistance/*drug effects
MH  - Etanercept
MH  - Female
MH  - Health Status
MH  - Humans
MH  - Immunoglobulin G/adverse effects/therapeutic use
MH  - Infliximab
MH  - Male
MH  - Matrix Metalloproteinase 3/blood
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor/therapeutic use
MH  - Remission Induction
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/immunology
EDAT- 2009/10/06 06:00
MHDA- 2010/05/07 06:00
CRDT- 2009/10/06 06:00
PHST- 2009/03/11 00:00 [received]
PHST- 2009/09/02 00:00 [accepted]
PHST- 2009/10/06 06:00 [entrez]
PHST- 2009/10/06 06:00 [pubmed]
PHST- 2010/05/07 06:00 [medline]
AID - 10.1007/s10165-009-0235-4 [doi]
PST - ppublish
SO  - Mod Rheumatol. 2010 Feb;20(1):40-5. doi: 10.1007/s10165-009-0235-4. Epub 2009 Oct 
      3.